Strategic Acquisition LimFlow is now part of Stryker, presenting a large-scale cross-sell opportunity to integrate LimFlow’s minimally invasive limb-threatening ischemia solution with Stryker's broader vascular and surgical portfolios.

CLTI Focus Target hospitals and clinics treating Chronic Limb-Threatening Ischemia with high amputation risk; position the LimFlow System as a minimally invasive alternative where traditional therapies fall short to drive adoption and reimbursement coverage.

Clinical Evidence Leverage the PROMISE I 24-month results and ongoing heterogeneous device studies to support value messaging on amputation-free survival and wound healing, accelerating payer discussions and clinical adoption.

Commercial Leadership With recent hires in commercial operations and health economics, pursue expansion in sales territories, hospital networks, and reimbursement pathways to scale adoption in mid-size and large healthcare systems.

Financing Momentum Capitalise on prior Series C and D funding by aligning with procurement teams on total cost of ownership, patient throughput improvements, and health economic value to support favorable contracting terms.